Last 0.32 GBp
Change Today 0.00 / 0.00%
Volume 0.0
VAL On Other Exchanges
Symbol
Exchange
London
As of 2:43 AM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

valirx plc (VAL) Snapshot

Open
0.32 GBp
Previous Close
0.33 GBp
Day High
0.32 GBp
Day Low
0.32 GBp
52 Week High
09/24/14 - 0.52 GBp
52 Week Low
04/28/14 - 0.26 GBp
Market Cap
9.4M
Average Volume 10 Days
16.3M
EPS TTM
-0.0015 GBp
Shares Outstanding
2.9B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALIRX PLC (VAL)

Related News

No related news articles were found.

valirx plc (VAL) Related Businessweek News

No Related Businessweek News Found

valirx plc (VAL) Details

ValiRx Plc, an investment holding company, is engaged in the research and development of technologies and products in oncology therapeutics and diagnostics in the United Kingdom. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of rebellious genes, which cause cancers, inflammatory conditions, and Alzheimer’s and autoimmune diseases. The company’s lead drug candidates in late stage pre-clinical development include VAL101, a novel therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that inhibits the process of apoptosis; and VAL201, a novel peptide for the treatment of hormone refractory prostate cancer, and other indications of hormone induced unregulated growth, including endometriosis. It is also developing ValiFinn BioMarkers that are diagnostic markers of inhibition of signaling pathways, which are target sites for novel drugs to treat cancer; and predictive markers of disease progression, as well as VAL401, a clinical drug to treat patients with lung cancer. The company is based in London, the United Kingdom.

9 Employees
Last Reported Date: 03/28/14

valirx plc (VAL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 182.5K GBP
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 74.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 118.0K GBP
Compensation as of Fiscal Year 2013.

valirx plc (VAL) Key Developments

ValiRx plc Enters into Collaboration Agreement with the Deutsches Krebsforschungszentrum

ValiRx Plc announced that it has entered into a collaboration agreement with the DKFZ for the further development of ValiRx's proprietary Gene Inactivation through Chromatin Engineering technology platform (known as GeneICE).  The goal of the research is to develop new targeting technologies that will improve the early detection and diagnosis of various cancers and new GeneICE compounds aimed at enhancing treatment outcomes.  The Agreement represents an extension of a strategic alliance with one of the biomedical research institutions, which is aimed at accelerating the translation of the preclinical evidence supporting the GeneICE technology's potential to silence specific 'rebellious genes' implicated in causing cancers, and take individualised cancer medicine from bench to bedside.  As a part of the Agreement, ValiRx retains all rights to GeneICE and improvements to the technology and has a first refusal on commercial rights to other IP deriving from the collaboration.

ValiRx plc Provides Further Development and Scientific Update on the Progress of Pre-Clinical Studies at Valiseek Limited

ValiRx Plc provided a further development and scientific update on the progress of pre-clinical studies at ValiSeek Limited. ValiSeek was formed to develop VAL401, the novel lung cancer treatment drug, through its remaining preclinical development and towards Clinical Efficacy (Phase II) trials for the treatment of lung cancer and potentially other oncology indications. Further to development update on 15 May 2014, ValiSeek now reports on the completion of the efficacy phase of pre-clinical testing for the use of VAL401 in non-small cell lung cancer. Studies demonstrated a mean response with at least a 50% reduction in the rate of tumour growth in an accepted standard cancer model. Furthermore, no adverse effects were seen during the course of the experiment, which comprised six weeks of continuous treatment at three differing dose levels. The Company believes that these positive and exciting results confirm the promise shown by the earlier reported cellular assay results. These in vivo study results will form the foundation of a submission for scientific advice to the MHRA for its review of the planned clinical development programme for VAL401. The formulation and preliminary pre-clinical toxicology results are expected be collated and reported by the end of 2014. Further efficacy studies will be carried out in due course to establish the potential utility of VAL401 and its broad spectrum use against solid adenocarcinoma tumours or cancers of hormone responsive glandular origin, which include prostate, breast and pancreatic cancers and other small cell lung cancers.

ValiRx Plc Reports Unaudited Consolidated Earnings Results for the Half Year Ended June 30, 2014

ValiRx Plc reported unaudited consolidated earnings results for the half year ended June 30, 2014. For the half year, the company reported revenue of £59,574 compared to £103,999 a year ago. Operating loss was £1,139,028 compared to £1,576,992 last year. Loss before taxation was £1,493,032 compared to £1,572,699 last year. Loss and total comprehensive income attributable to owners of the parent was £1,748,481 or 0.05 pence per basic and diluted share compared to £1,632,099 or 0.09 pence per basic and diluted share last year. Cash outflows from operating activities were £1,701,700 compared to £1,022,398 last year. Payments to acquire intangible assets were £162,881 compared to £70,447 last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VAL:LN 0.32 GBp 0.00

VAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAL.
View Industry Companies
 

Industry Analysis

VAL

Industry Average

Valuation VAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 107.1x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 107.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALIRX PLC, please visit www.valirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.